From Medscape Infectious Diseases:
Emerging Antibiotics: Will We Have What We Need?
" * More US patients die of MRSA infections than HIV/AIDS and tuberculosis combined.
* Only 2 new antibiotics -- doripenem and telavancin -- have been approved in the past 3 years.
* We have no drugs to treat infections with some strains of multi-drug-resistant gram-negative bacilli, like Pseudomonas aeruginosa and Acinetobacter baumannii.We may finally have arrived at the era of the untreatable bacterial infection."The ESKAPE ( they effectively escape the effects of antibiotics)
Emerging Antibiotics: Will We Have What We Need?
" * More US patients die of MRSA infections than HIV/AIDS and tuberculosis combined.
* Only 2 new antibiotics -- doripenem and telavancin -- have been approved in the past 3 years.
* We have no drugs to treat infections with some strains of multi-drug-resistant gram-negative bacilli, like Pseudomonas aeruginosa and Acinetobacter baumannii.We may finally have arrived at the era of the untreatable bacterial infection."The ESKAPE ( they effectively escape the effects of antibiotics)
E | Enterococcus faecium | Third most common cause of HCA BSI. Increasing resistance to vancomycin. |
S | Staphylococcus aureus (MRSA) | Emerging resistance to current drugs and significant drug toxicities. Lack of oral agents for step-down therapy |
K | Klebsiella Escherichia coli K pneumoniae |
ESBL-producing organisms increasing in frequency and severity; associated with increasing mortality. K pneumoniae carbapenemases causing severe infections in LTCF. Few active agents; nothing in development |
A | Acinetobacter baumannii | Increasing worldwide, recent surge reported in hospitals. Very high mortality. Carbapenem-resistant. |
P | Pseudomonas aeruginosa | Increasing P. aeruginosa infections in US and worldwide. Resistant to carbapenems, quinolones, aminoglycosides |
E | Enterobacter species | MDR HCA infections increasing; resistance via ESBLs, carbapenemases, and cephalosporinases |